Table 1.

Incidence of brain metastases in NSCLC.

Whole Population	15–20%
EGFR mutant	15–20%
KRAS G12C mutant	10–12%
ALK rearranged	4–5%
MET mutant	2–3%
BRAF V600E mutant	1–5%
HER2 exon 20 mutant	1–3%
RET mutant	1–2%
ROS1 mutant	1–2%
NTRK mutant	<1%